en
Scientific article
Open access
English

Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients

Published inLiver transplantation, vol. 13, no. 5, p. 658-664
Publication date2007
Abstract

Sirolimus (SRL) has been proposed to replace calcineurin inhibitors (CNI) in case of CNI-induced toxicity. The aim of this study was to evaluate the efficacy and safety of conversion from CNI to SRL in maintenance liver transplantation (LT) patients. Between 2002 and 2006, conversion was performed in 48 patients (17 female, 31 male; mean age 57 +/- 10 yr) after a median delay of 19.4 months (range 0.2-173 months) after LT. Indication for conversion was renal impairment (RI) (78%), CNI neurotoxicity (13%), or post-LT cancer (9%). Median follow-up was 22.6 +/- 11 months. Median SRL dosage and trough levels were 2.4 +/- 1.3 mg and 8.1 +/- 2.7 microg/L. Immunosuppression consisted of SRL alone (33%), or SRL + mycophenolate mofetil (MMF) (39%), SRL + prednisone (15%), SRL + CNI (4%), or SRL + MMF + prednisone (8%). Mean glomerular filtration rate (GFR) improved from 33 to 48 mL/minute in patients with severe RI (P = 0.022) and from 56 to 74 mL/minute in patients with moderate RI (P = 0.0001). After conversion, main complications were albuminuria (36%), hyperlipidemia (49%), dermatitis (14%), edema (14%), oral ulcers (12%), joint pain (4%), infection (2%), and pneumonia (2%). Acute rejection (AR) occurred in 17% of the patients. SRL was withdrawn in 17% of the patients. In conclusion, conversion from CNI to SRL is safe and is associated with significant renal function improvement.

Keywords
  • Aged
  • Calcineurin/antagonists & inhibitors
  • Feasibility Studies
  • Female
  • Follow-Up Studies
  • Glomerular Filtration Rate/drug effects
  • Humans
  • Immunosuppressive Agents/adverse effects/therapeutic use
  • Kidney/drug effects/physiopathology
  • Liver Transplantation/adverse effects
  • Male
  • Middle Aged
  • Neoplasms/etiology
  • Nervous System Diseases/chemically induced
  • Postoperative Care
  • Retreatment
  • Sirolimus/adverse effects/therapeutic use
  • Treatment Outcome
Citation (ISO format)
MORARD, Isabelle et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. In: Liver transplantation, 2007, vol. 13, n° 5, p. 658–664. doi: 10.1002/lt.21116
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal1527-6465
723views
1523downloads

Technical informations

Creation03/27/2014 12:05:00 PM
First validation03/27/2014 12:05:00 PM
Update time03/14/2023 9:03:10 PM
Status update03/14/2023 9:03:09 PM
Last indexation01/16/2024 9:29:52 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack